AZN · story · 29 October – 30 October
AstraZeneca · 4 headlines from 4 outlets, from 29 October 2026 to 30 October 2026.
AstraZeneca and Gosselaar launched a cancer biomarker testing awareness campaign.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
BioSpace is the largest at 4.2, ahead of People.com (3.3). Traders Union is the smallest at 0.8.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| BioSpace | 4.2 |
| People.com | 3.3 |
| Fierce Pharma | 2.5 |
| Traders Union | 0.8 |
| Outlet | Headlines | Average tone |
|---|---|---|
| BioSpace | 1 | +4.2 |
| People.com | 1 | +3.3 |
| Fierce Pharma | 1 | +2.5 |
| Traders Union | 1 | +0.8 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +2.5 | Awareness campaign supporting biomarker testing for patients. |
| +0.8 | Marketing campaign launch while shares trade sideways. |
| Tone | What the article reported, and why it scored that way |
|---|---|
| +4.2 | Awareness campaign on biomarker testing with a celebrity; mildly positive brand activity. |
| +3.3 | Interview tied to company-backed testing awareness campaign. |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.